Chicago Capital LLC Reduces Stake in PROCEPT BioRobotics

Investment firm cuts holdings in medical robotics company by 24.1% in Q4 2025

Apr. 18, 2026 at 7:37am

Got story updates? Submit your updates here. ›

An extreme close-up of the intricate mechanical components and gears of a medical robotic system, rendered in a high-contrast, industrial style that conveys a sense of power, precision, and technological innovation.The complex inner workings of a cutting-edge medical robot highlight the technological advancements driving the growing field of robotic healthcare solutions.Chicago Today

Chicago Capital LLC, an investment management firm, reduced its stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 24.1% during the fourth quarter of 2025, according to a recent SEC filing. The firm now owns 1,190,995 shares of the medical robotics company, valued at $37.47 million.

Why it matters

PROCEPT BioRobotics is a leading developer of robotic systems for minimally invasive treatment of benign prostatic hyperplasia (BPH). The company's flagship product, the AquaBeam Robotic System, has gained traction in the market, but its stock price has been volatile in recent quarters.

The details

Chicago Capital LLC sold 377,850 shares of PROCEPT BioRobotics during the fourth quarter, reducing its stake in the company to 2.13%. Several other institutional investors, including Alliancebernstein L.P., Westfield Capital Management Co. LP, and Mackenzie Financial Corp, have also made significant investments in PROCEPT BioRobotics in recent quarters.

  • Chicago Capital LLC filed its SEC disclosure on April 18, 2026.
  • The firm reduced its PROCEPT BioRobotics holdings during the fourth quarter of 2025.

The players

Chicago Capital LLC

An investment management firm that has reduced its stake in PROCEPT BioRobotics Corporation.

PROCEPT BioRobotics Corporation

A medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH).

Got photos? Submit your photos here. ›

The takeaway

The reduction in Chicago Capital's PROCEPT BioRobotics holdings reflects the ongoing volatility in the medical robotics sector, as investors weigh the company's growth potential against broader market conditions. However, PROCEPT BioRobotics remains a key player in the BPH treatment market, with several institutional investors maintaining significant stakes in the company.